Larimar Reports Positive Initial Data From Long-term OLE Study Of Nomlabofusp In Friedreich's Ataxia
(RTTNews) - Larimar Therapeutics, Inc. (LRMR), Monday announced positive initial data from the long-term open label extension (OLE) study of nomlabofusp in participants with Friedreich's Ataxia.
Friedreich's ataxia is a genetic, progressive, neurodegenerative disorder.
Data from the OLE study showed that treatment with nomlabofusp raised frataxin levels in participants. Friedreich's ataxia is caused by frataxin deficiency, and increase in frataxin levels may lead to the slowing of progression of the disease.
The company added that it remains on track to initiate a registrational study of nomlabofusp in mid-2025. It plans to submit Biologics License Application (BLA) in the second half of 2025.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.